FY25 consensus $8.94. Backs FY25 revenue $64.1B-$65.6B, consensus $65.01B. Outlook Revised to Reflect Negative Impact From Anticipated One-Time Charge of Approximately 6c per Share Related to License Agreement With Hengrui Pharma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck reports Q1 adjusted EPS $2.22, consensus $2.14
- Notable companies reporting before tomorrow’s open
- CoreWeave initiated, eBay downgraded: Wall Street’s top analyst calls
- Trump looking at cutting drug prices to international levels, Reuters says
- Merck initiated with a Neutral at Cantor Fitzgerald